3-year follow-up of obinutuzumab, ibrutinib and venetoclax for cll
Published 3 years ago • 1.2K plays • Length 6:34Download video MP4
Download video MP3
Similar videos
-
2:43
four-year follow-up from a phase ii study of obinutuzumab, ibrutinib, and venetoclax in cll
-
1:11
acalabrutinib-obinutuzumab in cll: 3-year follow-up
-
2:00
obinutuzumab, ibrutinib, and venetoclax in high-risk cll: the cll2-give and cll13 trials
-
1:13
5-year follow-up of patients with cll treated in first-line with ibrutinib plus venetoclax
-
4:31
sequence of administration of ibrutinib with obinutuzumab in r/r cll patients
-
2:30
ascend: 3 year follow-up of acalabrutinib in r/r cll
-
4:44
7-year update on a phase ii trial of fixed-duration obinutuzumab, ibrutinib, and venetoclax for cll
-
8:42
my must-have products for sjogren's syndrome
-
5:29
long term follow-up with ibrutinib venetoclax to treat chronic lymphocytic leukemia
-
3:40
the role of dll3-directed agents in treating sclc
-
1:34
the mutational profile in patients with cll treated with acalabrutinib or ibrutinib
-
1:23
interim analysis of the flair study: efficacy of ibrutinib plus venetoclax in ighv unmutated cll
-
1:39
overview of the cllr3 trial of obinutuzumab
-
1:36
cll2-give trial: ibrutinib, venetoclax and obinutuzumab in patients with tp53-mutated cll
-
1:25
illuminate 4-year follow up: obinutuzumab w/ ibrutinib vs w/ chlorambucil
-
1:56
ibrutinib plus venetoclax for first-line treatment of cll: 4-year follow-up data
-
0:49
overview of the cll2-big trial of ibrutinib and obinutuzumab
-
0:59
5-year follow-up results of cll14: obinutuzumab venetoclax vs obinutuzumab chlorambucil in cll
-
2:58
results of a phase ib study of ibrutinib obinutuzumab in r/r cll
-
1:59
acalabrutinib, venetoclax and obinutuzumab upfront for cll
-
1:56
emerging ibrutinib-based combinations in cll
-
0:56
fixed-duration treatment strategies for frontline and relapsed cll